Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the
cancer more sensitive to the antiviral agent ganciclovir.
PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who
have stage IV melanoma.